How to deal with side effects of Momelotinib

As a new JAK1/JAK2 inhibitor, momelotinib has shown good efficacy in the treatment of myelofibrosis (MF), but like most targeted drugs, patients may still encounter certain adverse reactions during use. Correctly understanding these side effects and taking appropriate treatment methods are key to ensuring efficacy and patient compliance.

The more common side effects include gastrointestinal discomfort, such as nausea, diarrhea and loss of appetite, which can generally be alleviated by adjusting the diet structure, eating small amounts more often, and using symptomatic drugs when necessary. Some patients will experience mild to moderate headaches or fatigue. Most of these conditions are more obvious in the early stages of treatment and will improve as the body gradually adapts to the medication. Anemia is a common problem in patients with myelofibrosis, and molotinib has certain advantages over other JAK inhibitors. Not only does it not significantly aggravate anemia, but it can also improve hemoglobin levels in some patients, but blood pictures still need to be monitored regularly.

In individual cases, patients may experience an increased risk of infection or mild abnormalities in liver function parameters. Doctors usually conduct regular checks before medication and during treatment. If any abnormalities are found, they can be resolved by suspending or adjusting the dosage. For patients with chronic underlying diseases, such as diabetes or hypertension, they need to pay more attention to the control of underlying diseases during medication to reduce drug-related risks.

In addition, if patients experience persistent fatigue, significant weight loss, or unexplained fever during treatment, they should report to the doctor in time to rule out drug-related complications. Overseas clinical practice experience shows that most side effects can be effectively managed through supportive treatment and reasonable monitoring, and complete discontinuation of medication is rarely required. Overall, the management of adverse reactions of molotinib emphasizes the principle of individualization, and doctors will adopt differentiated plans according to the patient's specific conditions.

Reference materials:https://en.wikipedia.org/wiki/Momelotinib